UA107088C2 - 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину - Google Patents
5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестеринуInfo
- Publication number
- UA107088C2 UA107088C2 UAA201204339A UAA201204339A UA107088C2 UA 107088 C2 UA107088 C2 UA 107088C2 UA A201204339 A UAA201204339 A UA A201204339A UA A201204339 A UAA201204339 A UA A201204339A UA 107088 C2 UA107088 C2 UA 107088C2
- Authority
- UA
- Ukraine
- Prior art keywords
- salts
- trifluoroethoxy
- hydroxycyclohexyl
- nicotinamide
- dichlorophenyl
- Prior art date
Links
- -1 2-hydroxycyclohexyl Chemical group 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 title 1
- 230000002124 endocrine Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170097 | 2009-09-11 | ||
| PCT/EP2010/063136 WO2011029827A1 (en) | 2009-09-11 | 2010-09-08 | 5- (3, 4-dichloro-phenyl) -n- (2-hydroxy-cyclohexyl) -6- (2,2, 2-trifluoro-ethoxy) -nico tinamide and salts thereof as hdl cholesterol raising agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA107088C2 true UA107088C2 (xx) | 2014-11-25 |
Family
ID=42830122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201204339A UA107088C2 (xx) | 2009-09-11 | 2010-08-09 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US8227491B2 (OSRAM) |
| EP (1) | EP2475645B1 (OSRAM) |
| JP (1) | JP5604520B2 (OSRAM) |
| KR (1) | KR101382871B1 (OSRAM) |
| CN (1) | CN102639506B (OSRAM) |
| AR (2) | AR078352A1 (OSRAM) |
| AU (1) | AU2010294277B2 (OSRAM) |
| BR (1) | BR112012005511B8 (OSRAM) |
| CA (1) | CA2771493C (OSRAM) |
| CL (1) | CL2012000611A1 (OSRAM) |
| CO (1) | CO6491033A2 (OSRAM) |
| CR (1) | CR20120089A (OSRAM) |
| CY (1) | CY1114377T1 (OSRAM) |
| DK (1) | DK2475645T3 (OSRAM) |
| EC (1) | ECSP12011723A (OSRAM) |
| ES (1) | ES2423821T3 (OSRAM) |
| HR (1) | HRP20130869T1 (OSRAM) |
| IL (1) | IL217920A (OSRAM) |
| IN (1) | IN2012DN00763A (OSRAM) |
| MA (1) | MA33563B1 (OSRAM) |
| MX (1) | MX2012002254A (OSRAM) |
| MY (1) | MY161103A (OSRAM) |
| NZ (1) | NZ597514A (OSRAM) |
| PE (1) | PE20120863A1 (OSRAM) |
| PL (1) | PL2475645T3 (OSRAM) |
| PT (1) | PT2475645E (OSRAM) |
| RS (1) | RS52987B (OSRAM) |
| RU (1) | RU2541475C2 (OSRAM) |
| SG (1) | SG179035A1 (OSRAM) |
| SI (1) | SI2475645T1 (OSRAM) |
| TW (1) | TWI412363B (OSRAM) |
| UA (1) | UA107088C2 (OSRAM) |
| WO (1) | WO2011029827A1 (OSRAM) |
| ZA (1) | ZA201201599B (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012031817A1 (en) * | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| WO2014180741A1 (en) * | 2013-05-06 | 2014-11-13 | F. Hoffmann-La Roche Ag | Methods of identifying modulators of osbpl7 and the use of such modulators for treatment of diseases associated with osbpl7 |
| US20200085810A1 (en) * | 2018-07-26 | 2020-03-19 | Hoffmann-La Roche Inc. | Compounds for use in treating kidney disorders |
| US11814354B2 (en) | 2021-09-08 | 2023-11-14 | River 3 Renal Corp. | Solid forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI259180B (en) * | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| BRPI0609685A2 (pt) | 2005-04-06 | 2010-04-20 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para tratamento e/ou profilaxia de enfermidades que estão associados com a modulação de receptores de cb1, e utilização dos mesmos |
| RU2454405C2 (ru) * | 2006-10-04 | 2012-06-27 | Ф.Хоффманн-Ля Рош Аг | Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина |
-
2010
- 2010-08-09 UA UAA201204339A patent/UA107088C2/ru unknown
- 2010-09-03 US US12/875,196 patent/US8227491B2/en active Active
- 2010-09-08 DK DK10749873.5T patent/DK2475645T3/da active
- 2010-09-08 MY MYPI2012001104A patent/MY161103A/en unknown
- 2010-09-08 SG SG2012016127A patent/SG179035A1/en unknown
- 2010-09-08 MX MX2012002254A patent/MX2012002254A/es active IP Right Grant
- 2010-09-08 CA CA2771493A patent/CA2771493C/en active Active
- 2010-09-08 BR BR112012005511A patent/BR112012005511B8/pt active IP Right Grant
- 2010-09-08 NZ NZ597514A patent/NZ597514A/xx unknown
- 2010-09-08 SI SI201030327T patent/SI2475645T1/sl unknown
- 2010-09-08 TW TW099130367A patent/TWI412363B/zh active
- 2010-09-08 ES ES10749873T patent/ES2423821T3/es active Active
- 2010-09-08 RU RU2012113924/04A patent/RU2541475C2/ru active
- 2010-09-08 PT PT107498735T patent/PT2475645E/pt unknown
- 2010-09-08 RS RS20130395A patent/RS52987B/sr unknown
- 2010-09-08 AU AU2010294277A patent/AU2010294277B2/en active Active
- 2010-09-08 WO PCT/EP2010/063136 patent/WO2011029827A1/en not_active Ceased
- 2010-09-08 KR KR1020127008704A patent/KR101382871B1/ko active Active
- 2010-09-08 JP JP2012528344A patent/JP5604520B2/ja active Active
- 2010-09-08 PL PL10749873T patent/PL2475645T3/pl unknown
- 2010-09-08 EP EP10749873.5A patent/EP2475645B1/en active Active
- 2010-09-08 HR HRP20130869AT patent/HRP20130869T1/hr unknown
- 2010-09-08 IN IN763DEN2012 patent/IN2012DN00763A/en unknown
- 2010-09-08 CN CN201080039932.7A patent/CN102639506B/zh active Active
- 2010-09-08 PE PE2012000302A patent/PE20120863A1/es active IP Right Grant
- 2010-09-09 AR ARP100103303A patent/AR078352A1/es not_active Application Discontinuation
-
2012
- 2012-01-12 CO CO12004250A patent/CO6491033A2/es active IP Right Grant
- 2012-02-02 IL IL217920A patent/IL217920A/en active IP Right Grant
- 2012-02-21 CR CR20120089A patent/CR20120089A/es unknown
- 2012-03-02 ZA ZA2012/01599A patent/ZA201201599B/en unknown
- 2012-03-03 EC ECSP12011723 patent/ECSP12011723A/es unknown
- 2012-03-05 MA MA34662A patent/MA33563B1/fr unknown
- 2012-03-08 CL CL2012000611A patent/CL2012000611A1/es unknown
-
2013
- 2013-09-05 CY CY20131100768T patent/CY1114377T1/el unknown
-
2018
- 2018-11-16 AR ARP180103371A patent/AR114032A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| GB0906579D0 (en) | Pharmaceuticals, compositions and methods of making and using the same | |
| MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
| UA114906C2 (uk) | Гетероциклільні сполуки як інгібітори мек | |
| MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| NZ603837A (en) | Novel nicotinamide derivative or salt thereof | |
| WO2013064900A8 (en) | Oral immediate release formulations for substituted quinazolinones | |
| BR112014004435A2 (pt) | inibidores de quinase rock | |
| MX2014000779A (es) | Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide. | |
| MX2013002660A (es) | Heteroarilmetilamidas. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| CL2013003372A1 (es) | Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes. | |
| PH12013500007A1 (en) | Piperidine derivatives and their use for the treatment of metabolic disorders | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| AR114032A2 (es) | 5-(3,4-dicloro-fenil)-n-(2-hidroxi-ciclohexil)-6-(2,2,2-trifluor-etoxi)-nicotinamida y sales de la misma | |
| EA201390984A1 (ru) | Гетероциклические соединения, подходящие для лечения дислипидемии | |
| MX357446B (es) | Agente terapeutico para dislipidemia. | |
| MA28706B1 (fr) | Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques | |
| CL2012002621A1 (es) | Polimorfo forma i, ii, iii, iv y vi de 4-trifluorometil-n-(3,3a,4,4a,5,5a,6,6a-octahidro-1,3-dioxo-4,6-etenocicloprop[f]isoindol-2(1h)-il)-benzamida (st-246); metodo para producirlas; composicion farmaceutica; forma de dosificacion unitaria; y metodo de tratamiento de infecciones por ortopoxvirus y de eczema vacunal. | |
| MX2014005715A (es) | N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica. | |
| MX2014001862A (es) | 5-cicloalquil-o 5-heterociclil-nicotinamidas. | |
| BR112014002915A2 (pt) | inibidores de pde4 suaves | |
| BR112014016450A2 (pt) | composto antagonista de leucotrieno b4 |